Skip to main content
. Author manuscript; available in PMC: 2020 Feb 21.
Published in final edited form as: Clin Gastroenterol Hepatol. 2018 May 8;17(3):486–493. doi: 10.1016/j.cgh.2018.04.060

Figure 2:

Figure 2:

Figure 2:

Figure 2:

Figure 2:

Change in clinical and biochemical markers of disease activity following vedolizumab a) Crohn’s disease clinical response and remission rates b) Mean (SEM) HBI in patients with Crohn’s disease c) Ulcerative colitis clinical response and remission rates d) Mean (SEM) SCCAI in patients with ulcerative colitis